Granite Point Capital Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Granite Point Capital Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-42,000	Closed	-$2.61M	–	110
2019 Q4	$2.61M	Hold	42,000	–	–	0.41%	32
2019 Q3	$1.43M	Buy	+42,000	New	+$1.24M	0.22%	35

Other funds holding DCPH

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Granite Point Capital Management's DCPH Position: Q1 2020 in Review

Granite Point Capital Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2020, closing a stake of 42,000 shares — an estimated $2.61M sold.

Granite Point Capital Management first reported a position in DCPH in Q3 2019 and held it in 2 quarters. The position peaked at $2.61M in Q4 2019. 148 funds tracked by Wall St. Rank hold DCPH as of Q1 2020.

Granite Point Capital Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Granite Point Capital Management sold 42,000 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $2.61M.
Granite Point Capital Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
Granite Point Capital Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $2.61M in Q4 2019.
148 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Granite Point Capital Management's 13F filing for Q1 2020, filed 12 May 2020.